Accueil | Fils de syndication
Afficher l'Article
CLINICAL THERAPEUTICS: Sublingual Immunotherapy
Onsdag den 21. Maj 2008 - kl. 06:55 - 7 måneder, 3 uger depuis - Presse spécialisée - New England Journal of Medicin
A 28-year-old man presents with allergic rhinitis, primarily due to grass pollen, that has not previously responded to antihistamines and nasal sprays. A trial of sublingual immunotherapy is recommended. Sublingual immunotherapy is more convenient than injection immunotherapy. However, only one agent, which is specific for grass-pollen allergies, has been approved for clinical use in some European countries. The Food and Drug Administration has not approved any agent for sublingual immunotherapy.
